The AMNOG procedure

infographic: The AMNOG procedure

Does the new drug have an added benefit versus standard treatment? This is the question to be investigated. To prove the drug’s added benefit, the pharmaceutical company prepares a dossier. Immediately after approval of the new drug, the company sends this dossier to the , which forwards it to IQWiG for scientific assessment. IQWiG prepares a so-called dossier assessment. Using this assessment, the then makes a decision on the added benefit, which serves as the basis for setting the price of the new drug.

Picture of

Jens Flintrop

press officer

Picture of

Susanne Breuer

press officer

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.